Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEP) Gross Margin (2025)

Coeptis Therapeutics Holdings (COEP) has 1 years of Gross Margin data on record, last reported at 80.98% in Q3 2025.

  • For Q3 2025, Gross Margin changed N/A year-over-year to 80.98%; the TTM value through Sep 2025 reached 72.96%, changed N/A, while the annual FY2021 figure was 100.0%, N/A changed from the prior year.
  • Gross Margin reached 80.98% in Q3 2025 per COEP's latest filing, up from 77.5% in the prior quarter.
  • Across five years, Gross Margin topped out at 80.98% in Q3 2025 and bottomed at 28.18% in Q1 2025.